Policy Developments - The National Healthcare Security Administration (NHSA) has initiated a crackdown on "returning drugs" through a "100-day action" plan, emphasizing comprehensive regulation across all stages of the drug supply chain [2] - The NHSA aims to enhance intelligent regulatory systems to preemptively manage healthcare fund oversight [2] Drug and Device Approvals - The FDA has approved Boehringer Ingelheim's small molecule tablet Jascayd (nerandomilast) for the treatment of idiopathic pulmonary fibrosis (IPF), marking the first new therapy for IPF in over a decade [5] - Roche and Jazz Pharmaceuticals received FDA approval for the PD-L1 inhibitor Tecentriq (atezolizumab) in combination with Zepzelca (lurbinectedin) as a first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC) [6] - Northeast Pharmaceutical announced that its DCTY0801 injection has received clinical trial approval for treating EGFRvIII positive recurrent or progressive high-grade glioma [7] - BaiLi Tianheng has received clinical trial approval for its innovative drug BL-ARC001 for advanced solid tumors, which is a first-in-class antibody-drug conjugate [9] Capital Markets - Chengyi Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with Jefferies, BofA Securities, and CICC as joint sponsors [11] - Changfeng Pharmaceutical's IPO on the Hong Kong Stock Exchange saw a significant opening increase of over 218%, trading at HKD 47 per share [12] Industry Developments - Innovent Biologics has entered into a licensing agreement with Zenas BioPharma for three autoimmune pipeline products, including a USD 100 million upfront payment and potential milestone payments exceeding USD 2 billion [14] - AstraZeneca has signed a USD 555 million collaboration agreement with Algen Biotechnologies to leverage AI for discovering new therapeutic targets in immunology [16][17]

Core Viewpoint - The company announced a licensing agreement with Zenas for its core product, Orelabrutinib, in the field of multiple sclerosis and other non-oncological treatments, while retaining rights in oncology [1][2]. Group 1: Licensing Agreement Details - The agreement includes a $100 million upfront payment and potential milestone payments, with a total deal value exceeding $2 billion [1]. - Zenas will also issue 7 million shares of common stock to the company, with additional payments tied to clinical development and commercialization milestones [1]. - The agreement allows Zenas to develop and commercialize Orelabrutinib globally for multiple sclerosis and other non-cancer indications [1][2]. Group 2: Product and Market Insights - Orelabrutinib is currently approved for three indications in hematological cancers in China, with ongoing clinical trials for multiple sclerosis [2]. - The company retains exclusive global rights for Orelabrutinib in oncology, establishing a dual strategy of self-research in oncology and licensing in autoimmune diseases [2]. - The new oral IL-17 AA/AF inhibitor and the brain-penetrant oral TYK2 inhibitor are in preclinical stages, targeting autoimmune diseases like psoriasis and psoriatic arthritis [3]. Group 3: Market Context and Future Prospects - The global market for multiple sclerosis treatments is significant, particularly in Europe and North America, where the disease has a higher prevalence [5]. - The company’s Orelabrutinib shows advantages in kinase selectivity and binding affinity, indicating strong clinical development potential [5]. - The oral IL-17 AA/AF inhibitor addresses the challenge of injection-based therapies, which may improve patient compliance [5]. Group 4: Financial Position - As of June 30, 2025, the company holds approximately 7.68 billion yuan in cash and equivalents, indicating a strong financial position within the biotech sector [6].

Core Viewpoint - Zenas BioSciences has entered into a transformative global licensing agreement worth over $2 billion with InnoCare Pharma, acquiring rights to three autoimmune disease drug candidates, including the previously abandoned BTK inhibitor orelabrutinib, indicating a growing trend of collaboration between multinational pharmaceutical companies and Chinese biotech firms [3][5][6]. Group 1: Financial Details - The agreement includes an initial payment of $100 million in cash, with additional milestone payments expected in the following year. Zenas will also issue up to 7 million shares of common stock to InnoCare, contingent on achieving specific milestones by early 2026 [6]. - InnoCare will receive milestone payments throughout the development, registration, and commercialization phases of the three drugs, with the total value of the agreement potentially exceeding $2 billion. Additionally, InnoCare will earn a tiered royalty rate of "high teens" (approximately 15%-19%) on the annual net sales of these drugs [6]. Group 2: Key Drug Candidates - The core asset of the deal is orelabrutinib, an oral BTK inhibitor capable of penetrating the central nervous system, which is crucial for treating multiple sclerosis (MS). This drug was previously licensed to Biogen, which terminated the agreement in early 2023 [8]. - Orelabrutinib is currently approved in China for treating chronic lymphocytic leukemia and mantle cell lymphoma, and it is in Phase III clinical trials globally for primary progressive MS, with plans for a late-stage global trial to start in Q1 2026 [8]. - In addition to orelabrutinib, Zenas has acquired two other drug candidates: obexelimab, a monoclonal antibody targeting B cells for various autoimmune diseases, and an oral IL-17AA/AF inhibitor, along with a brain-penetrating oral TYK2 inhibitor, both of which are still in early development stages [8][9].

潜在交易额超20亿美元 诺诚健华达成重磅对外授权协议 ◎记者 张雪 奥布替尼被寄予厚望 潜在总交易金额超20亿美元 诺诚健华将获得1亿美元的首付款及近期里程碑付款，以及Zenas发行的700万股普通股。未来，诺诚健 华还有权获得潜在的研发及注册里程碑付款、商业化里程碑付款，并从授权产品的年度净销售额中收取 最高达百分之十几的特许权使用费，总交易金额或将超过20亿美元。 奥布替尼是全球首个进入Ⅲ期临床的中枢神经系统强渗透性BTK抑制剂，针对原发进展型多发性硬化症 （PPMS）的全球Ⅲ期试验已于2025年三季度启动，预计2026年一季度启动继发进展型（SPMS）试 验。此前Ⅱ期数据显示，其显著减少脑部炎症病灶，且安全性优异。 通过此次合作，Zenas将获得奥布替尼在多发性硬化领域的全球独家开发、生产和商业化权利，以及奥 布替尼在非肿瘤领域除大中华区及东南亚地区以外区域的权利。Zenas还将获得口服IL-17AA/AF抑制剂 除大中华区及东南亚地区外的独家开发、生产和商业化权利，以及透脑性口服TYK2抑制剂的全球权 利。"我们预计2026年将这两款抑制剂推向临床，并预计2027年获得口服IL-17AA/AF抑制剂的 ...

Market Overview - Hong Kong stocks experienced a familiar pattern during the National Day holiday, with the Hang Seng Index dropping by 0.48% after one day of increase followed by three days of adjustment [1] - The U.S. government faced a shutdown starting October 1, affecting over 100,000 federal employees, with potential long-term negative impacts if the shutdown persists [1] - China's gold reserves increased to 7,406 million ounces by the end of September, marking the 11th consecutive month of accumulation [1] Gold and Silver Market - Ray Dalio, founder of Bridgewater, suggested that gold is a better hedge than the dollar and recommended a 15% allocation in investment portfolios as gold approaches $4,000 per ounce [2] - Chinese gold stocks such as Zijin Mining and Shandong Gold saw significant price increases, with Zijin rising over 13% and Shandong over 7% [2] - Silver prices also rose, with spot silver reaching $48.32 per ounce, reflecting a daily increase of 1% [2] Automotive Industry - The U.S. automotive sector is facing challenges, particularly after a fire at Novelis' Oswego plant, which supplies 40% of aluminum sheets for the industry, leading to production halts expected to last until early next year [2] - Tesla launched a "simplified" version of the Model Y at a lower price, but market reception appears lukewarm due to reduced features [2] Electric Vehicle Market - Chinese electric vehicle manufacturers are showing strong performance in Europe, with a 35% year-on-year increase in sales across nine major countries in September [3] - Companies like Xpeng, Geely, and BYD are expected to maintain positive trends as new models are set to launch in Q4 [3] Battery Technology - Advances in solid-state battery technology are being reported, with new materials developed that significantly enhance energy density [3] - Production rates are expected to increase by 5-10% in October, with a projected year-on-year growth of 30-50% [3] AI and Semiconductor Industry - OpenAI announced a partnership with AMD to deploy 6 GW of AMD GPU computing power, indicating continued investment in AI technology [4] - Nvidia is expected to play a significant role in a $20 billion funding round for Elon Musk's AI startup, xAI, highlighting the ongoing collaboration in the AI sector [4] Nuclear Fusion Developments - The BEST project in Anhui, China, achieved a key breakthrough, marking progress in nuclear fusion technology [5] - Germany plans to invest €2 billion in building the world's first nuclear fusion power plant by 2029 [5] Pharmaceutical Sector - Innovent Biologics announced a licensing agreement with Zenas Bio Pharma for the development and commercialization of its product, with potential total payments exceeding $2 billion [6] - Other companies in the sector may see increased activity due to potential milestone payments related to this agreement [6] Mining and Materials - China Metallurgical Group reported a decrease in new contract amounts but an increase in overseas contracts, indicating a shift in focus towards international operations [7] - The company is advancing projects in Afghanistan and Pakistan, which are expected to yield significant profits upon completion [8] - The company also has a strong position in silicon-based semiconductor materials, indicating long-term investment potential [9]

Core Insights - InnoCare Pharma Inc., a wholly-owned subsidiary of the company, has signed a licensing agreement with Zenas BioPharma, granting Zenas global development and commercialization rights for Orelabrutinib in multiple sclerosis and other non-oncology therapeutic areas [1] - Zenas will pay up to $100 million in upfront and milestone payments, with total transaction value exceeding $2 billion, including stock issuance and royalties [1] Group 1 - The agreement includes rights to two preclinical molecules: a novel oral IL-17 AA/AF inhibitor and a brain-penetrant oral TYK2 inhibitor [1] - Zenas will issue 7 million shares of common stock to the company, with additional payments tied to clinical development, registration, and commercialization milestones [1] - The company is entitled to receive tiered royalties of up to the high teens percentage on annual net sales of the licensed products [1]

Core Insights - The article highlights significant fluctuations in the market prices of silver and tin, which have impacted the stock price of Xingye Silver Tin [1] Performance - Chipone Technology expects a record high quarterly revenue of 1.284 billion yuan for Q3 [1] - Great Wall Motors reported a year-on-year sales increase of 23.29% in September [1] - Foton Motor's total vehicle sales in September grew by 6.08% year-on-year, with new energy vehicle sales increasing by 47.77% [1] - BYD experienced a year-on-year decline of 5.52% in new energy vehicle sales in September [1] - Seres saw a year-on-year sales increase of 8.33% in September [1] - BAIC Blue Valley's subsidiary reported a year-on-year sales increase of 30.15% in September [1] - Yonghe Holdings anticipates a year-on-year net profit increase of 211.59% to 225.25% for the first three quarters [1] Shareholding Changes - Huaxing Yuanchuang's shareholders plan to reduce their holdings by no more than 0.9% [1] - Ruile New Materials' shareholders intend to reduce their holdings by no more than 100,800 shares [1] Share Buybacks - Huaxin Cement plans to repurchase shares worth between 32.25 million and 64.5 million yuan [1] Contract Awards - Bomei Technology signed a contract for an offshore floating production storage and offloading vessel project, valued at approximately 190 to 240 million USD [1] - Sichuan Gold acquired exploration rights for the Kugezi-Juebei gold mine in Xinjiang [1] - Weisheng Information won projects totaling 287 million yuan, accounting for 10.45% of the company's expected revenue for 2024 [1] - Innovent Biologics' subsidiary signed a licensing agreement for the drug Orelabrutinib and two preclinical assets, with a total transaction value exceeding 2 billion USD [1] - Runjian Co. plans to bid for a land-based wind power project worth 1.753 billion yuan [1] - Xinjiang Jiaojian intends to bid for a highway construction project valued at 483 million yuan [1] Equity Changes - Delixi Holdings is planning a change in company control, leading to a stock suspension [1] - Bofei Electric plans to transfer 100% equity of its wholly-owned subsidiary Bofei New Energy [1] Other Developments - Dianguang Media holds 4.1288 million shares of Ruili Technology through Dacheng Venture Capital, representing 2.2915% of its post-issue total share capital [1] - Huaxin Cement has terminated plans for a spin-off listing of its overseas subsidiary [1] - Baili Tianheng received approval for clinical trials of BL-ARC001 for late-stage solid tumor treatment [1] - *ST Gaohong received a notice of termination of listing [1] - *ST Jianyi plans to sign an agreement to terminate the investment cooperation for the monocrystalline silicon project and deregister Jianyi Zhengyao [1]

Major Events - Delixi Co., Ltd. is planning a change in control, with stock suspension starting from October 9, 2025, for up to two trading days [1] - Sichuan Gold has won the exploration rights for the Kugez—Juebei gold mine in Xinjiang for 510 million yuan, indicating significant mining potential in a key mineral belt [1] - *ST Gaohong received a notice of termination of listing due to stock prices being below 1 yuan for 20 consecutive trading days [2] - Baili Tianheng's innovative drug BL-ARC001 has received clinical trial approval for treating advanced solid tumors, marking a significant advancement in targeted therapy [3] - Xingye Silver Tin's stock price fluctuation is attributed to significant recent price changes in its main products, silver and tin [3] Performance Overview - BAIC Blue Valley's subsidiary reported a 30.15% year-on-year increase in September sales, totaling 20,539 vehicles [4] - Seres achieved a 19.44% year-on-year increase in September sales, reaching 44,700 new energy vehicles [4] - BYD's September sales of new energy vehicles decreased by 5.52% year-on-year, totaling 396,300 vehicles, with exports of 71,256 vehicles [5] - Chipone Technology expects Q3 revenue of 1.284 billion yuan, a 119.74% increase from the previous quarter and a 78.77% increase year-on-year [5] - Yonghe Holdings anticipates a net profit increase of 448% to 507% for Q3, with projected profits of 456 million to 476 million yuan for the first three quarters [5] Major Contracts - Xinjiang Jiaojian has been awarded a 483 million yuan highway construction project [6] - Longquan Co. is a candidate for a project worth 50.76 million yuan, expected to positively impact revenue and profit [7] - Runjian Co. has secured a design and construction contract for a land-based wind power project valued at 1.753 billion yuan [8] - Innovent Biologics has signed a licensing agreement with Zenas BioPharma for the drug Obrutinib and two preclinical assets, with a total deal value exceeding 2 billion USD [8] Shareholding Changes - Huaxing Yuanchuang announced plans for its employee shareholding platforms to reduce their holdings by up to 0.9% of the company's total shares [9][10]

Core Viewpoint - InnoCare Pharma Inc., a wholly-owned subsidiary of the company, has signed a licensing agreement with Zenas BioPharma, Inc. to license the drug Orelabrutinib and two preclinical assets, allowing Zenas to develop, produce, and commercialize these products [1][3]. Transaction Details - The agreement was approved by the company's board on October 7, 2025, without the need for shareholder approval [3]. - The primary licensed product, Orelabrutinib, is a late-stage clinical oral small molecule BTK inhibitor with potential best-in-class advantages, currently undergoing Phase III clinical trials for multiple sclerosis and has completed patient enrollment for Phase III registration trials in immune thrombocytopenia [3]. Company and Partner Overview - Zenas BioPharma, established in November 2019 and listed on NASDAQ in September 2024, focuses on transformative therapies for autoimmune diseases and is advancing late-stage drugs like obexelimab and Orelabrutinib [3]. - There are no affiliations or other relationships between Zenas and the company or its subsidiaries [3]. Agreement Key Terms - Zenas will pay an upfront fee of $100 million and milestone payments, with total potential payments exceeding $2 billion, including royalties of up to 10% on annual net sales of the licensed products [5][6]. - The licensing agreement will be effective upon signing and will last until the expiration of the sales rights for the licensed products, after which Zenas will receive a permanent, irrevocable license [6]. Impact on the Company - The agreement is expected to accelerate the global development and commercialization of Orelabrutinib and other pipeline products, marking a significant milestone in the company's international strategy [5]. - The transaction is not expected to affect the company's business independence or create dependency [5].

Core Insights - The company announced a licensing agreement with Zenas BioPharma, granting Zenas rights to develop, produce, and commercialize the product Orelabrutinib and two preclinical assets [1][2] Group 1: Licensing Agreement Details - The agreement includes exclusive global rights for Orelabrutinib in multiple sclerosis (MS) and exclusive rights in other non-MS and non-cancer indications outside Greater China and Southeast Asia [1] - The agreement also covers a preclinical IL-17 inhibitor and a preclinical oral TYK2 inhibitor, with exclusive rights outside Greater China and Southeast Asia for the former and global exclusive rights for the latter [1] Group 2: Financial Terms - Zenas will pay the company a $100 million upfront payment and milestone payments, including cash expected upon achieving milestones in 2026, along with 7 million shares of common stock [2] - The total potential payments from this transaction, including upfront, milestone, and commercial payments, could exceed $2 billion [2] - The company is entitled to receive tiered royalties of up to the high teens percentage based on the annual net sales of the licensed products [2]